TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. (formerly trading under SPAC ticker MTAC) is a commercial-stage medical device company focused on oncology drug delivery, specifically its pressure-enabled drug delivery platform designed to treat liver and pancreatic tumors. The company went public through a business combination with MedTech Acquisition Corp, a healthcare-focused blank check company that completed its IPO in 2021 and was sponsored by MedTech Acquisition Partners, LLC. The merger closed in 2022, transitioning the entity from a SPAC into an operating public company within the healthcare and medical devices sector. The 10-Q filed August 2, 2023 covers post-combination quarterly operations as TriSalus advances commercialization of its TriNav Infusion System. Sign up at SpacDesk for full filing history, deal terms, and real-time data on this and hundreds of other SPAC transactions.